Additionally, there was no clear prognostic role of SRRT expression levels when they were combined with either intact PTEN or ERG loss to define patient populations with the worst clinical outcome, suggesting a potential “passenger” activity for SRRT when we take into account the molecular heterogeneity of lethal prostate cancer. The gene discussed is SRRT; the disease is Familial prostate cancer.